Central Retinal Vein Occlusion Clinical Trial
— SCORE2Official title:
Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
Verified date | June 2021 |
Source | The Emmes Company, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.
Status | Completed |
Enrollment | 362 |
Est. completion date | March 2021 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants must have center-involved macular edema secondary to CRVO. Eyes may be enrolled as early as the time of diagnosis of the macular edema. The definition of CRVO used in SCORE will also be used for the purposes of SCORE2: a CRVO is defined as an eye that has retinal hemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g., telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in all 4 quadrants. - Due to the similarities of a hemiretinal vein occlusion (HRVO) to CRVO,HRVO will be classified as CRVO for the purposes of this clinical trial. Eyes classified as having a HRVO will be limited to no more than 25% of the planned sample size. A HRVO is defined as an eye that has retinal hemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g. telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in 5 or more clock hours but less than all 4 quadrants. Typically, a HRVO is a retinal vein occlusion that involves 2 altitudinal quadrants. - E-Early Treatment Diabetic Retinopathy Study (ETDRS)visual acuity score of greater than or equal to 19 letters (approximately 20/400) and less than or equal to 73 letters (approximately 20/40) by the ETDRS visual acuity protocol. The investigator must believe that a study eye with visual acuity between 19 and 33 letters is perfused. - Retinal thickness on SD-OCT measurement, defined as central subfield thickness of 300 µm or greater. If the SD-OCT measurement is taken from a Heidelberg Spectralis Machine, the central subfield thickness should be 320 µm or greater. - Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs. Exclusion Criteria: - A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of major tranquilizers indicating difficulty in long term follow-up, likelihood of survival of less than 12 months). - Participation in an investigational trial within 30 days of study entry that involved treatment with any drug that has not received regulatory approval at time of study entry. - History of allergy to any anti-VEGF agent, corticosteroid, or component of the delivery vehicle. - The participant will be moving out of the area of the clinical site to an area not covered by another clinical site during the 12 months of the study. - Positive urine pregnancy test: all women of childbearing potential (those who are pre-menopausal and not surgically sterilized) may participate only if they have a negative urine pregnancy test, and if they do not intend to become pregnant during the timeframe of the study. Women who are sexually active with a male partner must agree to use at least one of the following birth control methods: hormonal therapy such as oral, implantable or injectable chemical contraceptives; mechanical therapy such as spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. - Women who are breast-feeding. - Examination evidence of vitreoretinal interface disease (e.g., vitreomacular traction, epiretinal membrane), either on clinical examination or OCT thought to be contributing to macular edema. - An eye that, in the investigator's opinion, would not benefit from resolution of macular edema such as eyes with foveal atrophy, dense pigmentary changes or dense subfoveal hard exudates. - Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, iris neovascularization, Irvine-Gass Syndrome, prior macula-off rhegmatogenous retinal detachment). - Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract). - History of laser photocoagulation for macular edema within 3 months prior to randomization. - History of intravitreal corticosteroid within 4 months of randomization. - Intravitreal anti-VEGF injection within 2 months of randomization. Note: Enrollment will be limited to no more than 25% of the planned sample size with any history of anti-VEGF treatment. Once this number of eyes has been enrolled, any history of anti-VEGF treatment will be an exclusion criterion. For enrollment of study eyes with prior intravitreal anti-VEGF agents, in the opinion of the investigator, the treatment response to prior anti-VEGF treatment must be either incomplete or the study eye had developed recurrent CRVO-associated macular edema, such that the study eye would benefit from additional anti-VEGF treatment. - History of peribulbar or retrobulbar corticosteroid use for any reason within 2 months prior to randomization. - History of panretinal scatter photocoagulation (PRP) or sector laser photocoagulation within 3 months prior to randomization or anticipated within the next 3 months following randomization. - History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within 4 months prior to randomization or anticipated within the next 6 months following randomization. - History of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to randomization. - Aphakia. - Presence of an anterior chamber intraocular lens - Examination evidence of external ocular infection, including conjunctivitis, chalazion or significant blepharitis. - History of macular detachment. - Examination evidence of any diabetic retinopathy. |
Country | Name | City | State |
---|---|---|---|
United States | Retina Research Institute of Texas | Abilene | Texas |
United States | Texas Retina Associates | Arlington | Texas |
United States | Emory University Eye Center | Atlanta | Georgia |
United States | Southeast Retina Center | Augusta | Georgia |
United States | The Retina Research Center | Austin | Texas |
United States | Elman Retina Group, PA | Baltimore | Maryland |
United States | Charlotte Eye Ear Nose & Throat Associates, P.A. | Charlotte | North Carolina |
United States | The Retina Group of Washington | Chevy Chase | Maryland |
United States | Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology | Chicago | Illinois |
United States | Retina Associates of Cleveland, Inc. | Cleveland | Ohio |
United States | The Ohio State University | Columbus | Ohio |
United States | Texas Retina Associates | Dallas | Texas |
United States | Henry Ford Health System | Detroit | Michigan |
United States | The Retina Group of Washington | Fairfax | Virginia |
United States | Carolinas Centers for Sight, PC | Florence | South Carolina |
United States | Retina Group of Florida | Fort Lauderdale | Florida |
United States | National Ophthalmic Research Institute | Fort Myers | Florida |
United States | Elman Retina Group, P.A. | Glen Burnie | Maryland |
United States | Cumberland Valley Retina Consultants | Hagerstown | Maryland |
United States | Charlotte Eye Ear Nose & Throat Associates, P.A. | Houston | Texas |
United States | Retina & Vitreous of Texas | Houston | Texas |
United States | Retina Consultants of Houston, PA | Houston | Texas |
United States | Thomas A. Ciulla, MD, PC | Indianapolis | Indiana |
United States | TLC Eyecare & Laser Centers | Jackson | Michigan |
United States | University of Florida, Dept of Ophthalmology | Jacksonville | Florida |
United States | Southeastern Retina Associates, PC | Knoxville | Tennessee |
United States | Florida Retina Consultants | Lakeland | Florida |
United States | Retina Consultants of Nevada | Las Vegas | Nevada |
United States | Delaware Valley Retina Associates | Lawrenceville | New Jersey |
United States | Sabates Eye Centers | Leawood | Kansas |
United States | Retina Associates of Kentucky | Lexington | Kentucky |
United States | University of Kentucky | Lexington | Kentucky |
United States | University of Wisconsin | Madison | Wisconsin |
United States | Georgia Retina, P.C. | Marietta | Georgia |
United States | Valley Retina Institute, PA | McAllen | Texas |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | VitreoRetinal Surgery | Minneapolis | Minnesota |
United States | Retina Vitreous Consultants | Monroeville | Pennsylvania |
United States | Northern California Retina Vitreous Associates | Mountain View | California |
United States | Tennessee Retina, PC | Nashville | Tennessee |
United States | Vanderbilt Eye Institute | Nashville | Tennessee |
United States | NJ Retina | New Brunswick | New Jersey |
United States | New England Retina Associates | New London | Connecticut |
United States | New York Eye and Ear Infirmary | New York | New York |
United States | East Bay Retina Consultants, Inc. | Oakland | California |
United States | Dean McGee Eye Institute | Oklahoma City | Oklahoma |
United States | UNMC Truhlsen Eye Institute | Omaha | Nebraska |
United States | Paducah Retinal Center | Paducah | Kentucky |
United States | Southern California Desert Retina Consultants | Palm Desert | California |
United States | Scheie Eye Institute | Philadelphia | Pennsylvania |
United States | Retinal Consultants of AZ | Phoenix | Arizona |
United States | Elman Retina Group, P.A. | Pikesville | Maryland |
United States | Casey Eye Institute / OHSU | Portland | Oregon |
United States | Retina Northwest, PC | Portland | Oregon |
United States | Black Hills Regional Eye Institute | Rapid City | South Dakota |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Retina Associates of Western New York | Rochester | New York |
United States | University of Rochester Flaum Eye Institute | Rochester | New York |
United States | Retinal Consultants Medical Group, Inc. | Sacramento | California |
United States | University of California Davis, Medical Center | Sacramento | California |
United States | The Retina Institute | Saint Louis | Missouri |
United States | Medical Center Ophthalmology Associates | San Antonio | Texas |
United States | Retinal Consultants of San Antonio | San Antonio | Texas |
United States | University of California, San Francisco | San Francisco | California |
United States | Sarasota Retina Institute | Sarasota | Florida |
United States | Retina Associates, PA | Shawnee Mission | Kansas |
United States | Charlotte Eye Ear Nose & Throat Associates, P.A. | Statesville | North Carolina |
United States | Retina Vitreous Surgeon of CNY, PC | Syracuse | New York |
United States | Retina Centers, P.C. | Tucson | Arizona |
United States | Palmetto Retina Center | West Columbia | South Carolina |
United States | Center for Retina and Macular Disease | Winter Haven | Florida |
United States | Florida Retina Consultants | Winter Haven | Florida |
Lead Sponsor | Collaborator |
---|---|
The Emmes Company, LLC | Milton S. Hershey Medical Center, National Eye Institute (NEI), University of Wisconsin, Madison |
United States,
Etheridge T, Blodi B, Oden N, Van Veldhuisen P, Scott IU, Ip MS, Mititelu M, Domalpally A. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15. Ophthalmol Retina. 2020 Dec 26. pii: S2468-6530(20)30503-0. doi: 10.1016/j.oret.2020.12.016. [Epub ahead of print] — View Citation
Etheridge T, Dobson ETA, Wiedenmann M, Oden N, VanVeldhuisen P, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A. Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14. Transl Vis Sci Technol. 2021 Mar 1;10(3):31. doi: 10.1167/tvst.10.3.31. — View Citation
Etheridge T, Dobson ETA, Wiedenmann M, Papudesu C, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A. A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study. PLoS One. 2020 Apr 30;15(4):e0232494. doi: 10.1371/journal.pone.0232494. eCollection 2020. — View Citation
Hendrick A, VanVeldhuisen PC, Scott IU, King J, Blodi BA, Ip MS, Khurana RN, Oden NL; SCORE2 Investigator Group. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials. Am J Ophthalmol. 2021 Feb;222:185-193. doi: 10.1016/j.ajo.2020.08.030. Epub 2020 Aug 20. — View Citation
Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. JAMA Ophthalmol. 2019 Mar 1;137(3):281-287. doi: 10.1001/jamaophthalmol.2018.6111. — View Citation
Peterson JS, Rockwell K Jr, Scott IU, Ip MS, VanVeldhuisen PC, Blodi BA; SCORE2 Investigator Group. LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS. Retina. 2019 Sep;39(9):1802-1809. doi: 10.1097/IAE.0000000000002212. — View Citation
Scott IU, Figueroa MJ, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE2 Investigator Group. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol. 2017 Dec;184:147-156. doi: 10.1016/j.ajo.2017.10.008. Epub 2017 Oct 23. — View Citation
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Altaweel M, Berinstein DM; SCORE2 Investigator Group. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Apr 1;136(4):337-345. doi: 10.1001/jamaophthalmol.2017.6843. — View Citation
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occ — View Citation
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU; SCORE2 Investigator Group. SCORE2 Report 2: Study Design and Baseline Characteristics. Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038. Epub 2016 Nov 15. — View Citation
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M; SCORE2 Investigator Group. SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion. Am J Ophthalmol. 2016 Oct;170:25-31. doi: 10.1016/j.ajo.2016.07.011. Epub 2016 Jul 19. — View Citation
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, King J, Antoszyk AN, Peters MA, Tolentino M; SCORE2 Investigator Group. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 | The primary analysis is based on observed data at 6 months. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters on an electronic visual acuity tester at a 3 meter distance according to a specific algorithm. A letter score is provided that ranges from 0 (unable to ready any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent. | Month 0 to 6 | |
Secondary | Number of Study Eyes With Gain of =15 Letters in Visual Acuity Letter Score at Month 6 | The measure is the number of study eyes that gained at least 15 letters in their visual acuity letter score at month 6 | Month 0 to 6 | |
Secondary | Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6 | The measure is the number of study eyes with a visual acuity letter score of 70 (Snellen equivalent of 20/40) or better at month 6 | Month 0 to 6 | |
Secondary | Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness | The measure is the mean central subfield thickness at month 6 measured by spectral-domain optical coherence tomography | Month 0 to 6 | |
Secondary | Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6 | The measure is calculated by subtracting the baseline central subfield thickness from the month 6 central subfield thickness | Month 0 to 6 | |
Secondary | Number of Study Eyes With Central Subfield Thickness <300 µm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces | The measure is the number of study eyes with central subfield thickness <300 µm, no subretinal fluid, no intraretinal fluid, and no cystoid spaces at month 6 | Month 0 to 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03981549 -
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
|
Phase 1/Phase 2 | |
Completed |
NCT02274259 -
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
|
Phase 4 | |
Completed |
NCT01360385 -
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
|
N/A | |
Not yet recruiting |
NCT00383773 -
Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
|
N/A | |
Completed |
NCT00952614 -
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
|
N/A | |
Recruiting |
NCT04601701 -
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Withdrawn |
NCT03417401 -
Surgical Stabilizer Assisted RVC With rtPA for CRVO
|
Phase 1 | |
Completed |
NCT01976312 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
|
Phase 3 | |
Completed |
NCT01724554 -
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
|
Phase 1/Phase 2 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01011374 -
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03223714 -
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT01827722 -
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
|
Phase 4 | |
Completed |
NCT00906685 -
Bevacizumab for Central Retinal Vein Occlusion Study
|
Phase 3 | |
Active, not recruiting |
NCT04793100 -
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
|
N/A | |
Recruiting |
NCT02405741 -
Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A |